ワクチンの世界市場:サブユニットワクチン、弱毒生ワクチン、結合型ワクチン、不活化ワクチン、 組換え型ワクチン、トキソイドワクチン等

◆英語タイトル:Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019
◆発行会社/調査会社:MarketsandMarkets
◆商品コード:MAM-BT-3113
◆発行日:2015年1月26日
◆調査対象地域:世界
◆産業分野:製薬
◆ページ数:211
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[ワクチンの世界市場:サブユニットワクチン、弱毒生ワクチン、結合型ワクチン、不活化ワクチン、 組換え型ワクチン、トキソイドワクチン等]についてメールでお問い合わせはこちら
当調査レポートでは、ワクチンの世界市場について調査・分析し、以下の構成でお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・市場インサイト
・市場概観
・バリューチェーン分析
・市場シェア分析
・市場環境分析
・ワクチンの世界市場:技術別分析/市場規模
・ワクチンの世界市場:種類別分析/市場規模
・ワクチンの世界市場:需要先別分析/市場規模
・地域別分析/市場規模
・競争状況
・関連企業分析
*** レポート概要(サマリー)***

The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. The global vaccines market is categorized on the basis of type, technology, disease indication, end user, and geography. The preventive vaccines segment is expected to register the highest growth rate in the vaccines market, by type, during the forecast period. Its favorable growth is attributed to the rising prevalence of diseases and increasing number of government initiatives taken for immunization programs worldwide.

Major factors contributing to growth of the vaccines market include rising prevalence of diseases, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in November 2014, the U.K. government granted $2 billion (£1.32 billion) to GAVI for the improvement of immunization programs in poor countries. The emerging markets of the Asian region have opened an array of opportunities for the vaccines market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of this market.

Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by the industry players over the last three years. In addition, the company profiles comprise the basic views on the key players in the vaccines market and the product portfolios, developments, and strategies adopted by the market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of the future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios of the top players in the vaccines market. The report analyzes the vaccines market by type, technology, disease indication, end users, and geography
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
• Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the vaccines market
• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various vaccines across geographies
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the vaccines market

*** レポート目次(コンテンツ)***

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 23
1.5 LIMITATIONS 23
1.6 STAKEHOLDERS 23

2 RESEARCH METHODOLOGY 24
2.1 MARKET SIZE ESTIMATION 25
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.3 MARKET SHARE ESTIMATION 28
2.4 KEY DATA FROM SECONDARY SOURCES 29
2.5 KEY DATA FROM PRIMARY SOURCES 29
2.6 KEY INDUSTRY INSIGHTS 30
2.7 ASSUMPTIONS 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 35
4.1 VACCINES MARKET HAS HIGH GROWTH POTENTIAL 35
4.2 VACCINES MARKET, BY TYPE 36
4.3 VACCINES MARKET, BY REGION 37
4.4 VACCINES MARKET, BY DISEASE INDICATION 38
4.5 VACCINES MARKET, BY END USER 39
4.6 LIFECYCLE ANALYSIS, BY REGION 40

5 MARKET OVERVIEW 41
5.1 INTRODUCTION 42
5.2 MARKET SEGMENTATION 42
5.2.1 VACCINES MARKET, BY TECHNOLOGY 42
5.2.2 VACCINES MARKET, BY TYPE 42
5.2.3 VACCINES MARKET, BY DISEASE INDICATION 43
5.2.4 VACCINES MARKET, BY END USER 43
5.2.5 VACCINES MARKET, BY REGION 44

5.3 MARKET DYNAMICS 45
5.3.1 DRIVERS 45
5.3.1.1 High prevalence of diseases 45
5.3.1.2 Rising government and nongovernment funding for vaccine development 46
5.3.1.3 Increasing investments by companies 46
5.3.1.4 Technological advancements 47
5.3.2 RESTRAINTS 48
5.3.2.1 Huge capital investments 48
5.3.2.2 Stringent regulatory procedures 48
5.3.3 OPPORTUNITIES 49
5.3.3.1 High growth prospects in emerging markets 49
5.3.3.2 Therapeutic vaccines 49
5.3.3.3 Adjuvant vaccines 50
5.3.4 CHALLENGES 51
5.3.4.1 Inadequate access to vaccines 51
5.3.4.2 Vaccine pricing 51
5.3.5 BURNING ISSUES 52
5.3.5.1 Failure of vaccines 52

6 INDUSTRY INSIGHTS 53
6.1 PORTER’S FIVE FORCES ANALYSIS 53
6.1.1 THREAT FROM NEW ENTRANTS 53
6.1.2 BARGAINING POWER OF SUPPLIERS 54
6.1.3 BARGAINING POWER OF BUYERS 54
6.1.4 INTENSITY OF COMPETITIVE RIVALRY 54
6.1.5 THREAT OF SUBSTITUTES 54
6.2 VALUE CHAIN ANALYSIS 54
6.3 SUPPLY CHAIN ANALYSIS 55
6.4 TECHNOLOGY TRENDS FOR ADJUVANTS 57
6.4.1 DRIVERS 57
6.4.1.1 Increasing Use of Adjuvants in Vaccine-preventable Diseases 57
6.4.1.2 Rising Government Investments 57
6.4.2 RESTRAINS 57
6.4.2.1 High Cost of Research 57
6.4.2.2 Regulatory Hurdles 58
6.4.3 OPPORTUNITIES 58
6.4.3.1 Combined Adjuvants 58
6.4.3.2 Vaccines for Young Children 58
6.4.3.3 Pandemic Diseases 58
6.4.4 CHALLENGES 58
6.4.4.1 Identification of Adjuvants 58
6.4.4.2 Technological Limitations 58
6.4.5 TRENDS 59
6.4.5.1 Collaborations 59
6.4.5.2 New Adjuvant Technologies 59
6.5 INVESTMENT ANALYSIS 61
6.6 REGULATORY LANDSCAPE 64
6.6.1 NORTH AMERICA 64
6.6.2 EUROPE 65
6.6.3 ASIA 65
6.6.4 ROW 66
6.7 PATENT ANALYSIS 66
6.8 KEY PIPELINE PRODUCTS 68
6.9 STRATEGIC BENCHMARKING 70

7 VACCINES MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
7.2 SUBUNIT VACCINES 74
7.3 LIVE ATTENUATED VACCINES 77
7.4 CONJUGATE VACCINES 79
7.5 INACTIVATED VACCINES 81
7.6 RECOMBINANT VECTOR VACCINES 84
7.7 TOXOID VACCINES 87
7.8 SYNTHETIC VACCINES 89
7.9 DENDRITIC CELL VACCINES 93

8 VACCINES MARKET, BY TYPE 95
8.1 INTRODUCTION 96
8.2 PREVENTIVE VACCINES 97
8.3 THERAPEUTIC VACCINES 100

9 VACCINES MARKET, BY DISEASE INDICATION 103
9.1 INTRODUCTION 104
9.2 INFECTIOUS DISEASES 105
9.2.1 PNEUMOCOCCAL 108
9.2.2 INFLUENZA 109
9.2.3 DTP 109
9.2.4 HEPATITIS 109
9.2.5 ROTAVIRUS 110
9.2.6 VARICELLA 110
9.2.7 MENINGOCOCCAL 110
9.2.8 POLIO 111
9.2.9 MMR 111
9.2.10 OTHERS 112
9.3 CANCER 112
9.3.1 CERVICAL CANCER 115
9.3.2 OTHER CANCERS 115
9.4 ALLERGIES 116

10 VACCINES MARKET, BY END USER 119
10.1 INTRODUCTION 120
10.2 PEDIATRICS 121
10.3 ADULTS 124

11 GLOBAL VACCINES MARKET, BY REGION 127
11.1 INTRODUCTION 128
11.2 NORTH AMERICA 131
11.2.1 U.S. 133
11.2.2 CANADA 136
11.3 EUROPE 138
11.3.1 GERMANY 141
11.3.2 FRANCE 145
11.3.3 U.K. 147
11.3.4 ITALY 149
11.3.5 SPAIN 151
11.3.6 REST OF EUROPE (ROE) 153
11.4 ASIA 155
11.4.1 JAPAN 158
11.4.2 CHINA 160
11.4.3 INDIA 163
11.4.4 REST OF ASIA (ROA) 165
11.5 REST OF THE WORLD (ROW) 167

12 COMPETITIVE LANDSCAPE 171
12.1 OVERVIEW 171
12.2 MARKET SHARE ANALYSIS 171
12.3 COMPETITIVE SITUATION AND TRENDS 173
12.3.1 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS 174
12.3.2 REGULATORY APPROVALS 174
12.3.3 ACQUISITIONS 175
12.3.4 OTHER DEVELOPMENTS 176

13 COMPANY PROFILES 177
13.1 INTRODUCTION 177
13.2 GLAXOSMITHKLINE, PLC. 178
13.3 MERCK & CO., INC. 181
13.4 SANOFI PASTEUR 184
13.5 PFIZER, INC. 187
13.6 NOVARTIS AG 189
13.7 BAVARIAN NORDIC 192
13.8 CSL LIMITED 194
13.9 EMERGENT BIOSOLUTIONS, INC. 196
13.10 JOHNSON & JOHNSON 198
13.11 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA) 200
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

14 APPENDIX 202
14.1 RECENT DEVELOPMENTS 202
14.1.1 GLAXOSMITHKLINE, PLC. 202
14.1.2 SANOFI PASTEUR 203
14.1.3 NOVARTIS AG 204
14.1.4 EMERGENT BIOSOLUTIONS INC. 204
14.2 INSIGHTS FROM INDUSTRY EXPERTS 205
14.3 DISCUSSION GUIDE 206
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 209
14.6 RELATED REPORTS 210

LIST OF TABLES

TABLE 1 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET
GROWTH OF VACCINES 47
TABLE 2 HUGE CAPITAL INVESTMENT TO LIMIT THE MARKET GROWTH OF VACCINES 49
TABLE 3 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH
OF VACCINES 50
TABLE 4 INCREASING PREVALENCE OF DISEASES TO BOOST THE MARKET GROWTH
OF VACCINES 51
TABLE 5 NATIONAL INSTITUTES OF HEALTH (NIH) FUNDING FOR VACCINE DEVELOPMENT, 2011–2013 ($MILLION) 62
TABLE 6 REGULATORY AUTHORITIES IN EUROPE 65
TABLE 7 REGULATORY AUTHORITIES IN ASIA 66
TABLE 8 KEY PIPELINE VACCINES 68
TABLE 9 VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 74
TABLE 10 SUBUNIT VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 75
TABLE 11 NORTH AMERICA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 75
TABLE 12 EUROPE: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 76
TABLE 13 ASIA: SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 76
TABLE 14 LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 77
TABLE 15 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 78
TABLE 16 EUROPE: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 78
TABLE 17 ASIA: LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 79
TABLE 18 CONJUGATE VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 80
TABLE 19 NORTH AMERICA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 80
TABLE 20 EUROPE: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 81
TABLE 21 ASIA: CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 81
TABLE 22 INACTIVATED VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 83
TABLE 23 NORTH AMERICA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 83
TABLE 24 EUROPE: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 84
TABLE 25 ASIA: INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 84
TABLE 26 RECOMBINANT VECTOR VACCINES MARKET SIZE, BY REGION,
2012-2019 ($MILLION) 85
TABLE 27 NORTH AMERICA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 86
TABLE 28 EUROPE: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 86
TABLE 29 ASIA: RECOMBINANT VECTOR VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 87
TABLE 30 TOXOID VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 88
TABLE 31 NORTH AMERICA: TOXOID VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 88
TABLE 32 EUROPE: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 89
TABLE 33 ASIA: TOXOID VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 89
TABLE 34 SYNTHETIC VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 91
TABLE 35 NORTH AMERICA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 91
TABLE 36 EUROPE: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 92
TABLE 37 ASIA: SYNTHETIC VACCINES MARKET SIZE, BY COUNTRY, 2012-2019 ($MILLION) 92
TABLE 38 DENDRITIC CELL VACCINES MARKET SIZE, BY REGION, 2012-2019 ($MILLION) 93
TABLE 39 NORTH AMERICA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 93
TABLE 40 EUROPE: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 94
TABLE 41 ASIA: DENDRITIC CELL VACCINES MARKET SIZE, BY COUNTRY,
2012-2019 ($MILLION) 94
TABLE 42 VACCINES MARKET SIZE, BY TYPE, 2012–2019 ($MILLION) 97
TABLE 43 PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 98
TABLE 44 NORTH AMERICA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 98
TABLE 45 EUROPE: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 99
TABLE 46 ASIA: PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 99
TABLE 47 THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 101
TABLE 48 NORTH AMERICA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 101
TABLE 49 EUROPE: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 102
TABLE 50 ASIA: THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 102
TABLE 51 VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012–2019 ($MILLION) 105
TABLE 52 VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION,
2012-2019 ($MILLION) 106
TABLE 53 NORTH AMERICA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES,
BY COUNTRY, 2012–2019 ($MILLION) 106
TABLE 54 EUROPE: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY, 2012–2019 ($MILLION) 107
TABLE 55 ASIA: VACCINES MARKET SIZE FOR INFECTIOUS DISEASES, BY COUNTRY,
2012-2019 ($MILLION) 107
TABLE 56 INFECTIOUS DISEASES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 108
TABLE 57 VACCINES MARKET SIZE FOR CANCER, BY REGION, 2012–2019 ($MILLION) 113
TABLE 58 NORTH AMERICA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY,
2012–2019 ($MILLION) 113
TABLE 59 EUROPE: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY,
2012–2019 ($MILLION) 114
TABLE 60 ASIA: VACCINES MARKET SIZE FOR CANCER, BY COUNTRY,
2012–2019 ($MILLION) 114
TABLE 61 CANCER VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 115
TABLE 62 VACCINES MARKET SIZE FOR ALLERGIES, BY REGION, 2012–2019 ($MILLION) 116
TABLE 63 NORTH AMERICA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY,
2012–2019 ($MILLION) 117
TABLE 64 EUROPE: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY,
2012–2019 ($MILLION) 117
TABLE 65 ASIA: VACCINES MARKET SIZE FOR ALLERGIES, BY COUNTRY,
2012–2019 ($MILLION) 118
TABLE 66 VACCINES MARKET SIZE, BY END USER, 2012–2019 ($MILLION) 120
TABLE 67 VACCINES MARKET SIZE FOR PEDIATRICS, BY REGION, 2012–2019 ($MILLION) 122
TABLE 68 NORTH AMERICA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY,
2012–2019 ($MILLION) 122
TABLE 69 EUROPE: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY,
2012–2019 ($MILLION) 123
TABLE 70 ASIA: VACCINES MARKET SIZE FOR PEDIATRICS, BY COUNTRY,
2012–2019 ($MILLION) 123
TABLE 71 VACCINES MARKET SIZE FOR ADULTS, BY REGION, 2012–2019 ($MILLION) 124
TABLE 72 NORTH AMERICA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY,
2012–2019 ($MILLION) 125
TABLE 73 EUROPE: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY,
2012–2019 ($MILLION) 125
TABLE 74 ASIA: VACCINES MARKET SIZE FOR ADULTS, BY COUNTRY, 2012–2019 ($MILLION) 126
TABLE 75 VACCINES MARKET SIZE, BY REGION, 2012–2019 ($MILLION) 129
TABLE 76 NORTH AMERICA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 130
TABLE 77 EUROPE: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 130
TABLE 78 ASIA: VACCINES MARKET SIZE, BY COUNTRY, 2012–2019 ($MILLION) 130
TABLE 79 NORTH AMERICA: VACCINES MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 132
TABLE 80 NORTH AMERICA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 132
TABLE 81 NORTH AMERICA: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2012-2019 ($MILLION) 133
TABLE 82 NORTH AMERICA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 133
TABLE 83 U.S.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 135
TABLE 84 U.S.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 135
TABLE 85 U.S.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 136
TABLE 86 U.S.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 136
TABLE 87 CANADA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 137
TABLE 88 CANADA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 137
TABLE 89 CANADA: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2012-2019 ($MILLION) 138
TABLE 90 CANADA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 138
TABLE 91 EUROPE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 140
TABLE 92 EUROPE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 140
TABLE 93 EUROPE: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2012-2019 ($MILLION) 141
TABLE 94 EUROPE: VACCINES MARKET SIZE, BY END USERS, 2012-2019 ($MILLION) 141
TABLE 95 GERMANY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 143
TABLE 96 GERMANY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 143
TABLE 97 GERMANY: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2012-2019 ($MILLION) 144
TABLE 98 GERMANY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 144
TABLE 99 FRANCE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 145
TABLE 100 FRANCE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 146
TABLE 101 FRANCE: VACCINES MARKET SIZE, BY DISEASE INDICATION,
2012-2019 ($MILLION) 146
TABLE 102 FRANCE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 147
TABLE 103 U.K.: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 148
TABLE 104 U.K.: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 148
TABLE 105 U.K.: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 149
TABLE 106 U.K.: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 149
TABLE 107 ITALY: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 150
TABLE 108 ITALY: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 150
TABLE 109 ITALY: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 151
TABLE 110 ITALY: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 151
TABLE 111 SPAIN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 152
TABLE 112 SPAIN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 152
TABLE 113 SPAIN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 153
TABLE 114 SPAIN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 153
TABLE 115 ROE: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 154
TABLE 116 ROE: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 154
TABLE 117 ROE: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 155
TABLE 118 ROE: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 155
TABLE 119 ASIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 157
TABLE 120 ASIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 157
TABLE 121 ASIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 158
TABLE 122 ASIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 158
TABLE 123 JAPAN: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 159
TABLE 124 JAPAN: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 159
TABLE 125 JAPAN: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 160
TABLE 126 JAPAN: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 160
TABLE 127 CHINA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 161
TABLE 128 CHINA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 162
TABLE 129 CHINA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 162
TABLE 130 CHINA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 162
TABLE 131 INDIA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 164
TABLE 132 INDIA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 164
TABLE 133 INDIA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 165
TABLE 134 INDIA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 165
TABLE 135 ROA: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 166
TABLE 136 ROA: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 166
TABLE 137 ROA: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 167
TABLE 138 ROA: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 167
TABLE 139 ROW: VACCINES MARKET SIZE, BY TECHNOLOGY, 2012-2019 ($MILLION) 169
TABLE 140 ROW: VACCINES MARKET SIZE, BY TYPE, 2012-2019 ($MILLION) 169
TABLE 141 ROW: VACCINES MARKET SIZE, BY DISEASE INDICATION, 2012-2019 ($MILLION) 170
TABLE 142 ROW: VACCINES MARKET SIZE, BY END USER, 2012-2019 ($MILLION) 170
TABLE 143 RECENT AGREEMENTS AND COLLABORATIONS 174
TABLE 144 RECENT REGULATORY APPROVALS 175
TABLE 145 RECENT ACQUISITIONS 175
TABLE 146 RECENT OTHER DEVELOPMENTS 176
TABLE 147 EXCHANGE RATES (UTILIZED FOR CONVERSION OF GBP TO USD) 179
TABLE 148 EXCHANGE RATES (UTILIZED FOR CONVERSION OF EURO TO USD) 184
TABLE 149 EXCHANGE RATES (UTILIZED FOR THE CONVERSION OF DKK TO USD) 192


LIST OF FIGURES

FIGURE 1 VACCINES MARKET, BY TECHNOLOGY 21
FIGURE 2 RESEARCH METHODOLOGY 24
FIGURE 1 TOP-DOWN APPROACH 26
FIGURE 2 BOTTOM-UP APPROACH 26
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 27
FIGURE 4 DATA TRIANGULATION METHODOLOGY 28
FIGURE 5 VACCINE TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): SUBUNIT VACCINES TO GROW AT HIGHEST CAGR 31
FIGURE 6 PREVENTIVE VACCINES TO DOMINATE THE VACCINES MARKET 32
FIGURE 7 PEDIATRIC SEGMENT WILL BE THE LARGEST END-USER SEGMENT IN THE VACCINES MARKET 33
FIGURE 8 NORTH AMERICA TO HOLD LARGEST SHARE IN THE GLOBAL VACCINES MARKET 34
FIGURE 9 HIGH PREVALENCE OF DISEASES TO DRIVE MARKET GROWTH 35
FIGURE 10 PREVENTIVE VACCINES SEGMENT HELD THE LARGEST SHARE IN VACCINES MARKET, BY TYPE 36
FIGURE 11 U.S. COMMANDS ONE-THIRD OF THE MARKET 37
FIGURE 12 INFECTIOUS DISEASES SEGMENT TO WITNESS SIGNIFICANT GROWTH IN EMERGING ECONOMIES 38
FIGURE 13 PEDIATRICS SEGMENT WILL CONTINUE TO LEAD THE VACCINES END-USERS MARKET DURING THE FORECAST PERIOD 39
FIGURE 14 ASIA TO WITNESS HIGH GROWTH RATE IN THE VACCINES MARKET DURING FORECAST PERIOD 40
FIGURE 15 VACCINES MARKET SEGMENTATION: BY TECHNOLOGY 42
FIGURE 16 VACCINES MARKET SEGMENTATION: BY TYPE 42
FIGURE 17 VACCINES MARKET SEGMENTATION: BY DISEASE INDICATION 43
FIGURE 18 VACCINES MARKET SEGMENTATION: BY END USER 44
FIGURE 19 VACCINES MARKET SEGMENTATION: BY REGION 44
FIGURE 20 INCREASING GOVERNMENT SUPPORT FOR PANDEMIC THREATS LIKELY TO FUEL GROWTH OF VACCINES MARKET 45
FIGURE 21 PORTER’S FIVE FORCES ANALYSIS 53
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT AND MANUFACTURING PHASES 55
FIGURE 23 SUPPLY CHAIN ANALYSIS 56
FIGURE 24 COLD CHAIN MANAGEMENT 56
FIGURE 25 FDA-APPROVED VACCINE ADJUVANTS 60
FIGURE 26 LICENSED VACCINES CONTAINING ADJUVANTS 60
FIGURE 27 EXAMPLES OF VACCINE ADJUVANTS IN CLINICAL TRIALS 61
FIGURE 28 INVESTORS PLAY AN IMPORTANT ROLE IN THE VACCINES MARKET 61
FIGURE 29 VACCINE RESEARCH FUNDING, BY TYPE OF INVESTOR 63
FIGURE 30 U.S. GOVERNMENT AGENCIES HELD LARGEST SHARE OF THE HIV R&D
FUNDING IN 2013 63
FIGURE 31 REGULATORY APPROVAL PROCESS FOR VACCINES 64
FIGURE 32 NORTH AMERICA ACCOUNTED FOR THE LARGEST NUMBER OF PATENT FILINGS
IN 2012 67
FIGURE 33 THE U.S. ACCOUNTED FOR LARGEST NUMBER OF PATENT FILINGS ACROSS THE GLOBE (2012) 67
FIGURE 34 STRATEGIC BENCHMARKING: GLAXOSMITHKLINE, PLC. LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR ENHANCING PRODUCT OFFERINGS 71
FIGURE 35 SUBUNIT VACCINES SEGMENT TO GROW AT HIGHEST CAGR IN FORECAST PERIOD 73
FIGURE 36 NORTH AMERICA TO DOMINATE THE INACTIVATED VACCINES MARKET FROM 2014 TO 2019 82
FIGURE 37 TOXOID VACCINES MARKET IN ASIA WILL GROW AT HIGHEST
CAGR FROM 2014 TO 2019 90
FIGURE 38 PREVENTIVE VACCINES TO DOMINATE THE GLOBAL VACCINES MARKET FROM 2014 TO 2019 96
FIGURE 39 ASIA TO GROW AT THE HIGHEST CAGR FROM 2014 TO 2019 100
FIGURE 40 INFECTIOUS DISEASES SEGMENT TO DOMINATE THE VACCINES MARKET FROM 2014 TO 2019 104
FIGURE 41 THE PEDIATRICS END-USER SEGMENT WILL DRIVE THE VACCINES MARKET DURING THE FORECAST PERIOD 120
FIGURE 42 GEOGRAPHIC SNAPSHOT (2014): EMERGING MARKETS HOLD GROWTH OPPORTUNITIES 128
FIGURE 43 GEOGRAPHIC BENCHMARKING FOR VACCINES TECHNOLOGY MARKET 129
FIGURE 44 MARKET GROWTH WILL BE DRIVEN BY INCREASING R&D ACTIVITIES FOR DEVELOPMENT OF VACCINES 131
FIGURE 45 INFECTIOUS DISEASES SEGMENT WILL CONTINUE TO DRIVE THE VACCINES MARKET 134
FIGURE 46 GERMANY WILL CONTINUE TO DOMINATE THE VACCINES MARKET IN EUROPE 139
FIGURE 47 GERMAN VACCINES MARKET TO GROW AT THE HIGHEST CAGR IN EUROPE 142
FIGURE 48 VACCINES MARKET IN ASIA GROW AT THE HIGHEST CAGR 156
FIGURE 49 INDIAN VACCINES MARKET WILL HAVE HIGH GROWTH POTENTIAL 163
FIGURE 50 PREVENTIVE VACCINES WILL LEAD THE ROW VACCINES MARKET IN 2019 168
FIGURE 51 MAJOR PLAYERS SIGNED AGREEMENTS TO ENHANCE THEIR MARKET POSITIONS IN THE VACCINES MARKET 171
FIGURE 52 VACCINES MARKET SHARE, BY KEY PLAYER, 2013 172
FIGURE 53 BATTLE FOR MARKET SHARE: AGREEMENTS WAS THE KEY STRATEGY ADOPTED
BY MARKET PLAYERS 173
FIGURE 54 PRODUCT BENCHMARKING FOR TOP 5 MARKET PLAYERS 177
FIGURE 55 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT 178
FIGURE 56 MERCK & CO., INC.: COMPANY SNAPSHOT 181
FIGURE 57 SANOFI PASTEUR: COMPANY SNAPSHOT 184
FIGURE 58 PFIZER INC.: COMPANY SNAPSHOT 187
FIGURE 59 NOVARTIS AG: COMPANY SNAPSHOT 189
FIGURE 60 BAVARIAN NORDIC: COMPANY SNAPSHOT 192
FIGURE 61 CSL LIMITED: COMPANY SNAPSHOT 194
FIGURE 62 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT 196
FIGURE 63 JOHNSON & JOHNSON: COMPANY SNAPSHOT 198
FIGURE 64 ASTRAZENECA : COMPANY SNAPSHOT 200


*** レポートのキーワード ***

予防ワクチン、治療ワクチン、サブユニットワクチン、弱毒生ワクチン、結合型ワクチン、不活化ワクチン、 組換え型ワクチン、トキソイドワクチン、合成ワクチン、樹状細胞ワクチン、ワクチン技術、インフルエンザ ワクチン、癌ワクチン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"ワクチンの世界市場:サブユニットワクチン、弱毒生ワクチン、結合型ワクチン、不活化ワクチン、 組換え型ワクチン、トキソイドワクチン等"は"MarketsandMarkets社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。